Feuerstein just released a new article. Interesting comment contained in it
Sarepta also said it is looking for a medical meeting venue "in the coming months" to present 74-week data from the eteplirsen phase II trial.
Question: If the 74-week data were bad (patients treated with eteplirsen losing significant muscle function as measured by the 6-minute walk test) wouldn't it be considered a material event, and as such, need to be disseminated to investors immediately?
I think so, so Sarepta not rushing to disclose 74-week eteplirsen data is a good thing, suggesting that the durability of the drug's benefit is being maintained.
z, that's confirmation from srpt the 72 data is very positive; they're looking for the right medical confernce to present the results at; don't forget, the 48 week results were released via pr but they were also presented at the perth conference in early oct